Humana Inc. (HUM) To Go Ex-Dividend on June 28th

Humana Inc. (NYSE:HUM) declared a quarterly dividend on Thursday, April 18th, RTT News reports. Stockholders of record on Friday, June 28th will be paid a dividend of 0.885 per share by the insurance provider on Friday, July 26th. This represents a $3.54 annualized dividend and a dividend yield of 0.99%. The ex-dividend date of this dividend is Friday, June 28th.

Humana has raised its dividend payment by an average of 12.3% annually over the last three years. Humana has a payout ratio of 17.3% indicating that its dividend is sufficiently covered by earnings. Analysts expect Humana to earn $19.63 per share next year, which means the company should continue to be able to cover its $3.54 annual dividend with an expected future payout ratio of 18.0%.

Humana Trading Down 0.6 %

Shares of Humana stock opened at $355.88 on Wednesday. The stock has a market cap of $42.88 billion, a P/E ratio of 22.16, a P/E/G ratio of 2.10 and a beta of 0.53. The stock’s 50 day simple moving average is $341.39 and its 200-day simple moving average is $354.08. Humana has a 1-year low of $298.61 and a 1-year high of $530.54. The company has a debt-to-equity ratio of 0.77, a current ratio of 1.67 and a quick ratio of 1.67.

Humana (NYSE:HUM) last issued its earnings results on Wednesday, April 24th. The insurance provider reported $7.23 earnings per share for the quarter, topping the consensus estimate of $6.12 by $1.11. The business had revenue of $29.61 billion for the quarter, compared to analysts’ expectations of $28.52 billion. Humana had a return on equity of 17.76% and a net margin of 1.82%. The business’s revenue for the quarter was up 10.7% compared to the same quarter last year. During the same period in the previous year, the firm posted $9.38 EPS. Analysts predict that Humana will post 16.07 EPS for the current fiscal year.

Analysts Set New Price Targets

Several research firms have recently commented on HUM. UBS Group reduced their price target on shares of Humana from $334.00 to $326.00 and set a “neutral” rating on the stock in a research report on Thursday, April 25th. Royal Bank of Canada cut their target price on Humana from $415.00 to $353.00 and set an “outperform” rating on the stock in a research report on Thursday, April 25th. Barclays lowered their target price on shares of Humana from $356.00 to $310.00 and set an “equal weight” rating for the company in a research note on Tuesday, April 2nd. Baird R W upgraded shares of Humana to a “hold” rating in a research note on Thursday, May 30th. Finally, Oppenheimer lowered their target price on shares of Humana from $415.00 to $370.00 and set an “outperform” rating for the company in a research note on Thursday, April 25th. Fourteen analysts have rated the stock with a hold rating and eight have issued a buy rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Hold” and an average target price of $410.47.

About Humana

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.